Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 376

Sort by

Sort Order Select

Journal Articles

Development and Testing of a Glycoengineered Anti-ROR1 Antibody with Enhanced Capacity for Directing Antibody-Dependent Cellular Cytotoxicity (ADCC) of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, George Widhopf II, Christopher Oh, Christina Girgis, Charles E. Prussak, James B. Breitmeyer, Thomas J. Kipps

Blood (2023) 142 (Supplement 1): 6836.

https://doi.org/10.1182/blood-2023-187559

Published: 2023

Journal Articles

Defining Signaling Interactomes Involved in Non-Canonical Wnt Signaling By ROR1 or ROR2 in Hairy Cell Leukemia That Can Influence Cell Morphology and Migration

Matthew Cring, George Widhopf, Emanuela M. Ghia, Thomas J. Kipps

Blood (2023) 142 (Supplement 1): 4378.

https://doi.org/10.1182/blood-2023-189562

Published: 2023

Journal Articles

Combined Therapy of Zanubrutinib and Zilovertamab in the Inhibition of Invasive Capability of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, George F. Widhopf II, Thomas J. Kipps

Blood (2023) 142 (Supplement 1): 6517.

https://doi.org/10.1182/blood-2023-191114

Published: 2023

Journal Articles

Comparison of Venetoclax Based Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Benjamin M. Heyman, Michael Y. Choi, Thomas J. Kipps

Blood (2023) 142 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2023-188129

Published: 2023

Journal Articles

A Long-Term Analysis of Lenalidomide and Rituximab (R 2 ) for the Treatment of Chronic Lymphocytic Leukemia

Chung-Jiah J. Chen, Michael Y. Choi, Benjamin M. Heyman, Thomas J. Kipps

Blood (2023) 142 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2023-180126

Published: 2023

Journal Articles

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Paolo Ghia, William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan, Zoë Hunter, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 633.

https://doi.org/10.1182/blood-2023-187128

Published: 2023

Journal Articles

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Larissa Balaian, Mary Donohoe, Phoebe Mondala, George F. Widhopf II, Emanuela M. Ghia, Edward D. Ball, Anna Kulidjian, Inge Van Der Werf, Thomas J. Kipps, Catriona Jamieson

Blood (2022) 140 (Supplement 1): 3356–3357.

https://doi.org/10.1182/blood-2022-170128

Published: 2022

Journal Articles

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Blood (2022) 140 (Supplement 1): 1530–1533.

https://doi.org/10.1182/blood-2022-160335

Published: 2022

Journal Articles

Rituximab and High-Dose Methylprednisolone Debulking Prior to Venetoclax for Patients with Relapsed or Refractory CLL

Michael Y. Choi, Benjamin Heyman, Minya Pu, Emily Pittman, Karen Messer, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 12410–12411.

https://doi.org/10.1182/blood-2022-170897

Published: 2022

Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 224–227.

https://doi.org/10.1182/blood-2022-160338

Published: 2022

Journal Articles

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Hun Ju Lee, Michael Y. Choi, Tanya Siddiqi, Joanna M. Rhodes, William G. Wierda, Iris Isufi, Joseph M Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Michael Wang, Catriona Jamieson, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 566–568.

https://doi.org/10.1182/blood-2022-167153

Published: 2022

Journal Articles

Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, George F. Widhopf II, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 6991.

https://doi.org/10.1182/blood-2022-170209

Published: 2022

Journal Articles

Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Susan Klaeger, Eugen Tausch, Binyamin A. Knisbacher, Annie Apffel, Karl R Clauser, Corinne Williams, Clary Clish, Laura Z. Rassenti, Thomas J. Kipps, Kirsten Fischer, Michael Hallek, Michael A Gillette, Donna S. Neuberg, Gad Getz, DR Mani, Stephan Stilgenbauer, Catherine J. Wu, Steven A Carr

Blood (2022) 140 (Supplement 1): 9838–9839.

https://doi.org/10.1182/blood-2022-167843

Published: 2022

Journal Articles

Long-Term Analysis of Anti-CD20mab + HDMP for the Treatment of Patients with Chronic Lymphocytic Leukemia

Benjamin Heyman, Michael Y. Choi, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 12414–12415.

https://doi.org/10.1182/blood-2022-167662

Published: 2022

Journal Articles

Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment

Miguel Quijada Álamo, Laura Z. Rassenti, Emanuela M. Ghia, Tuan Tran, Monica Spydell, Elsa Molina, Claudia Pérez Carretero, Luis A. Corchete, Teresa González, Jesús María Hernández-Rivas, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 4113–4114.

https://doi.org/10.1182/blood-2022-166403

Published: 2022

Journal Articles

ROR1: an orphan becomes apparent

Thomas J. Kipps

Blood (2022) 140 (14): 1583–1591.

https://doi.org/10.1182/blood.2021014760

Published: 2022

Journal Articles

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Blood (2022) 140 (8): 839–850.

https://doi.org/10.1182/blood.2021015014

Published: 2022

Includes: Supplemental data

Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Blood (2022) 139 (22): 3278–3289.

https://doi.org/10.1182/blood.2021014488

Published: 2022

Includes: Supplemental data

Journal Articles

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Blood (2022) 139 (14): 2252–2256.

https://doi.org/10.1182/blood.2021013926

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda

Blood (2022) 139 (12): 1794–1806.

https://doi.org/10.1182/blood.2021011895

Published: 2022

Includes: Supplemental data

NARROW

Development and Testing of a Glycoengineered Anti-ROR1 Antibody with Enhanced Capacity for Directing Antibody-Dependent Cellular Cytotoxicity (ADCC) of Chronic Lymphocytic Leukemia Cells

Defining Signaling Interactomes Involved in Non-Canonical Wnt Signaling By ROR1 or ROR2 in Hairy Cell Leukemia That Can Influence Cell Morphology and Migration

Combined Therapy of Zanubrutinib and Zilovertamab in the Inhibition of Invasive Capability of Chronic Lymphocytic Leukemia Cells

Comparison of Venetoclax Based Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

A Long-Term Analysis of Lenalidomide and Rituximab (R 2 ) for the Treatment of Chronic Lymphocytic Leukemia

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Rituximab and High-Dose Methylprednisolone Debulking Prior to Venetoclax for Patients with Relapsed or Refractory CLL

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia

Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Long-Term Analysis of Anti-CD20mab + HDMP for the Treatment of Patients with Chronic Lymphocytic Leukemia

Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment

ROR1: an orphan becomes apparent

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only